BRPI0409127A - combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio - Google Patents

combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio

Info

Publication number
BRPI0409127A
BRPI0409127A BRPI0409127-2A BRPI0409127A BRPI0409127A BR PI0409127 A BRPI0409127 A BR PI0409127A BR PI0409127 A BRPI0409127 A BR PI0409127A BR PI0409127 A BRPI0409127 A BR PI0409127A
Authority
BR
Brazil
Prior art keywords
sodium bicarbonate
electriptan
combination
pharmaceutical combination
treating
Prior art date
Application number
BRPI0409127-2A
Other languages
English (en)
Inventor
Michael John Humphrey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0409127A publication Critical patent/BRPI0409127A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMBINAçãO FARMACêUTICA COMPREENDENDO ELETRIPTANO E BICARBONATO DE SóDIO". A presente invenção fornece uma combinação de (a) eletriptano, ou um seu sal farmaceuticamente aceitável, e (b) bicarbonato de sódio. A combinação proporciona uma absorção rápida de eletriptano, quando tomada oralmente. A combinação é útil para o tratamento ou prevenção de uma doença para a qual é indicado um agonista de 5-HT~ 1~, particularmente para o tratamento de enxaqueca ou para a prevenção de enxaqueca recorrente.
BRPI0409127-2A 2003-04-11 2004-03-31 combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio BRPI0409127A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination
PCT/IB2004/001115 WO2004089365A1 (en) 2003-04-11 2004-03-31 Pharmaceutical combination comprising eletriptan and sodium bicarbonate

Publications (1)

Publication Number Publication Date
BRPI0409127A true BRPI0409127A (pt) 2006-03-28

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409127-2A BRPI0409127A (pt) 2003-04-11 2004-03-31 combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio

Country Status (12)

Country Link
EP (1) EP1615635A1 (pt)
JP (1) JP2006522790A (pt)
AR (1) AR044009A1 (pt)
BR (1) BRPI0409127A (pt)
CA (1) CA2521902A1 (pt)
MX (1) MXPA05010070A (pt)
NL (1) NL1025908C2 (pt)
PA (1) PA8599901A1 (pt)
PE (1) PE20050086A1 (pt)
TW (1) TW200423929A (pt)
UY (1) UY28260A1 (pt)
WO (1) WO2004089365A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009142771A2 (en) * 2008-05-22 2009-11-26 Plus Chemicals, S.A. Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
JP6878021B2 (ja) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 トリプタンとアスコルビン酸を含有する医薬組成物
AU2019297360B2 (en) * 2018-07-03 2022-07-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (it) * 1986-08-01 1988-11-25 Zambon Spa Composizione farmaceutica ad attivita' analgesica
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
CO5261541A1 (es) * 1999-05-14 2003-03-31 Pfizer Prod Inc Terapia de combinacion para el tratamiento de la migrana
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
JP2006523620A (ja) * 2003-02-19 2006-10-19 バイオヴェイル ラボラトリーズ インコーポレイテッド 急速吸収選択的５−ｈｔ作用剤製剤

Also Published As

Publication number Publication date
JP2006522790A (ja) 2006-10-05
TW200423929A (en) 2004-11-16
CA2521902A1 (en) 2004-10-21
MXPA05010070A (es) 2005-11-23
WO2004089365A1 (en) 2004-10-21
NL1025908C2 (nl) 2005-11-22
PE20050086A1 (es) 2005-03-01
EP1615635A1 (en) 2006-01-18
AR044009A1 (es) 2005-08-24
PA8599901A1 (es) 2005-02-04
UY28260A1 (es) 2004-11-30
NL1025908A1 (nl) 2004-10-13

Similar Documents

Publication Publication Date Title
CY1121720T1 (el) (+)-2-[1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθυλσουλφονυλαιθυλ]-4-ακετυλαμινoϊσoϊνδoλινo-1,3-διonη: μεθοδοι χρησης και συνθεσεις αυτης
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
BR9912866A (pt) Composto ou uma forma tautomérica, sal ousolvato farmaceuticamente aceitável do mesmo,composição farmacêutica, processo para otratamento ou a prevenção de uma doença, fatorde risco ou condição, mediada por hppar alfa e/ouhppar gama, e uso de um composto
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
GB0324654D0 (en) Medicinal compounds
AR033855A1 (es) Composiciones y combinaciones de activador(es) del receptor de activacion de proliferacion peroxis0mal (ppar) e inhibidor(es) de absorcion de esterol, el uso de dichas composiciones o combinaciones para la manufactura de un medicamento para el tratamiento para indicaciones vasculares, diabetes, obes
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
MY138352A (en) Benzothiazole derivatives
BR0109966A (pt) Combinação de compostos orgânicos
BRPI0408858A (pt) uso de um inibidor de ibat ou, um sal, solvato, solvato de um tal sal ou uma pró-droga destes, farmaceuticamente aceitáveis, composição farmacêutica, e, método de tratamento e/ou profilaxia de constipação em um animal de sangue quente
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
TNSN05176A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
BR0311931A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BR9909617A (pt) Composição farmacêutica
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
BR0314844A (pt) Novo composto
BR0314843A (pt) Novo composto
BR9912588A (pt) Prevenção de recorrência de enxaqueca
HUP0204511A2 (en) Use of ppar activator or ligand in preparation of pharmaceutical compositions for treatment of bone diseas
BRPI0409127A (pt) combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
MA27262A1 (fr) Microcapsules pour la liberation retardee et controlee du perindopril

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/404, 9/20, 9/00; A61P 25/06

Ipc: A61K 31/404 (2011.01), A61K 9/20 (2011.01), A61K 9

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 10A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.